Clinical trial · Observational
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients' quality of life. PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-vomiting medicine during the first course of chemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Nausea | — | UNRESOLVED | — |
| Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy
- timeFrame
- Week 1 of FOLFOX chemotherapy
- measure
- Impact of Nausea and Vomiting on the Patient's Quality of Life as Measured by the Functional Living Index - Emesis Scale at 5-7 Days
- timeFrame
- Week 1
- description
- Scale describing impact of nausea and vomiting on quality of life on a seven-point Likert Scale with higher score indicating worse quality of life.
- measure
- Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy
- timeFrame
- week 1
- description
- Number of participants with factors associated with increased frequency of nausea in the first cycle of chemotherapy, including history of motion sickness, history of pregnancy-related morning sickness, history of prior chemotherapy, and history of nausea associated with prior chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of colorectal cancer * Currently receiving OR scheduled to receive the first course of either of the following chemotherapy regimens: * mFOLFOX6 * FOLFOX7 * No clinical or imaging evidence of brain metastasis PATIENT CHARACTERISTICS: * Able to maintain a diary and complete a standardized quality of life questionnaire in English PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 90 days since prior aprepitant
References
Publications (0)
Data not yet available